These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35296212)

  • 21. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of tuberculosis with anti-tumor necrosis factor-α therapy: substantially higher number of patients at risk in Asia.
    Navarra SV; Tang B; Lu L; Lin HY; Mok CC; Asavatanabodee P; Suwannalai P; Hussein H; Rahman MU
    Int J Rheum Dis; 2014 Mar; 17(3):291-8. PubMed ID: 24131578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis.
    Zhou M; Xu R; Kaelber DC; Gurney ME
    PLoS One; 2020; 15(3):e0229819. PubMed ID: 32203525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
    Armuzzi A; Lionetti P; Blandizzi C; Caporali R; Chimenti S; Cimino L; Gionchetti P; Girolomoni G; Lapadula G; Marchesoni A; Marcellusi A; Mennini FS; Salvarani C; Cimaz R
    Int J Immunopathol Pharmacol; 2014; 27(1 Suppl):11-32. PubMed ID: 24774504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP; Liossis SN; Sfikakis PP
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
    Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
    Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF inhibitors for psoriasis.
    Chima M; Lebwohl M
    Semin Cutan Med Surg; 2018 Sep; 37(3):134-142. PubMed ID: 30215629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving Post-induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
    Guido AJ; Crandall W; Homan E; Dotson J; Maltz RM; Donegan A; Drobnic B; Oates M; Boyle B
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):48-54. PubMed ID: 31503216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-neutralizing Antibodies against TNF-α blockers as Biomarkers of Therapy Effect Evaluation.
    Kraev K; Geneva-Popova M; Popova V; Popova S; Maneva A; Batalov A; Stankova T; Delcheva G; Stefanova K
    Folia Med (Plovdiv); 2020 Jun; 62(2):282-289. PubMed ID: 32666748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications.
    Conrad A; Neven B; Mahlaoui N; Suarez F; Sokol H; Ruemmele FM; Rouzaud C; Moshous D; Lortholary O; Blanche S; Lanternier F
    J Clin Immunol; 2021 Jan; 41(1):185-193. PubMed ID: 33150502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
    Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
    Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
    Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
    Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
    Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.